Fragment-based drug discovery takes a virtual turn

In the realm of modern drug discovery technologies, fragment-based approaches and virtual ligand screening are emerging alternative approaches to high-throughput screening (HTS). For as simple as it sounds, a hybrid approach in which fragments are discovered first in silico may be an unbeatable route to hit identification for some drug targets.